Latest Episodes
Episode 6
Evolving landscape of type 2 diabetes management (part 2)
Listen to our experts about relapse of type 2 diabetes after remission, benefits of early intervention and novel approaches in type 2 diabetes.
Episode 5
Insulin and diabetes technology: the future is now (part 2)
In this episode, our speakers discuss once-weekly insulins in type 1 and type 2 diabetes.
Episode 4
New insights in Incretin-based therapies (part 2)
This new episode will give you highlights on dual agonists mode of action.
Episode 6
Evolving landscape of type 2 diabetes management (part 2)
Chapter 1
Prof. Puder
Diabetologia Symposium: Remission of type 2 diabetes – fact or fiction?
Chapter 2
Dr. Kosinski
Benefits and drawbacks of early effective intervention in T2D
Chapter 3
Prof. Rudofsky
Therapy outside the box
Episode 5
Insulin and diabetes technology: the future is now (part 2)
Chapter 1
Dr. Kosinski
Fighting diabetes with tubes, scanners, and catheters
Chapter 2
Prof. Lehmann
Re-inventing the insulin experience: exploring the prospects of once-weekly insulins
Chapter 3
Prof. Lehmann
The future of multiple daily injection therapy
Episode 4
New insights in Incretin-based therapies (part 2)
Chapter 1
Dr. Gerber
Incretins: Impact on BMI
Chapter 2
Dr. Gariani
Dual incretin receptor agonists: Is GIP receptor agonism the key for success?
Chapter 3
Prof. Jornayvaz
Dual incretin receptor agonists: Is GIP receptor agonism the key for success?
Chapter 4
Prof. Nauck
INCSG Symposium: GLP-1 dual and multi-agonist peptides: which additional activities to dial in?
Episode 3
Evolving landscape of type 2 diabetes management (part 1)
Chapter 1
Prof. Jornayvaz
Glycemic targets revisited: What HbA1c goals should be followed in 2022
Chapter 2
Prof. Nauck
Remission of type 2 diabetes – fact or fiction?
Episode 2
Insulin and diabetes technology: the future is now (part 1)
Chapter 1
Dr. Fischli
Debate: Insulin-free type 2 diabetes treatment
Chapter 2
Dr. Gariani
Fighting diabetes with tubes, scanners, and catheters
Episode 1
New insights in Incretin-based therapies (part 1)
Chapter 1
Prof. Lehmann
54th Claude Bernard Lecture: An updated incretin concept for tomorrow
Chapter 2
Prof. Puder
Glucose lowering agents
Chapter 3
Dr. Gerber
Lessons from trials
This page is supported by:
Eli Lilly (Suisse) SA
Ch. des Coquelicots 16
1214 Vernier, Geneva
The content of this page is intended for Swiss physicians.
For further information on our Lilly products and therapeutic areas, please contact our Medical Information:
Service hours: Monday-Friday, 8:30-15:00 hrs
Phone: +41 44 654 57 52
E-Mail: ch_medinfo@lilly.com
PP-NB-CH-0037/11.2022